CLAIMS

WHAT IS CLAIMED IS:

1. A formulation comprising from about 1 mg/ml to about 150 mg/ml of an anti-CD105 antibody, or antigen-binding fragment thereof, from about 5mM to about 100 mM of a buffering agent, from about 50mM to about 1 M of a polyol, and a pH of about 4.0 to about 7.5.

2. The formulation of claim 1, wherein at least 95% of the anti-CD105 antibody is present as a monomer following storage at about 2 to 8° C for at least 12 months as measured by size exclusion chromatography (SEC).

3. The formulation of claim 1, wherein at least 95% of the anti-CD105 antibody is present as a monomer following storage at about 25° C for at least 6 months as measured by size exclusion chromatography (SEC).

4. The formulation of claim 1, wherein at least 90% of the anti-CD105 antibody is present as a monomer following storage at about 25° C for at least 6 months as measured by size exclusion chromatography (SEC).

5. The formulation of claim 1, wherein said buffering agent is histidine or phosphate buffered saline.

6. The formulation of claim 1, wherein the buffering agent is acetate and the pH is about 4.

7. The formulation of claim 1 wherein the buffering agent is histidine and the pH is about 5.5.

8. The formulation of claim 1, wherein the anti-CD105 antibody, or antigen-binding fragment thereof, displays about 80 to 150% binding by a CD105 ELISA binding assay after storage at about 2 to 8 °C for at least 12 months.

9. The formulation of claim 1, wherein the average isoelectric point (pI) of the anti-CD105 antibody is from about 8.7 to about 9.2 after storage at 2 to 8° C for at least 12 months, as measured by capillary electrophoresis-isoelectric focusing.

10. The formulation of claim 1, wherein said anti-CD105 antibody comprises a light chain variable region (V_L) having an amino acid sequence set forth as SEQ ID NO: 1; a light chain constant region (C_L) having an amino acid sequence set forth as SEQ ID NO: 2; a heavy chain variable region (V_H) having an amino acid sequence set forth as SEQ ID NO: 3; and a constant region (Fc) having an amino acid sequence set forth as SEQ ID NO: 4.

11. The formulation of claim 1, wherein said anti-CD105 antibody comprises a V_L CDR1 having an amino acid sequence set forth as SEQ ID NO: 5; a V_L CDR2 having an amino acid sequence set forth as SEQ ID NO: 6; a V_L CDR3 having an amino acid sequence set forth as

SEQ ID NO: 7; a V_H CDR1 having an amino acid sequence set forth as SEQ ID NO: 8; a V_H CDR2 having an amino acid sequence set forth as SEQ ID NO: 9; and a V_H CDR3 having an amino acid sequence set forth as SEQ ID NO: 10.

12. The formulation of claim 1, comprising about 25 mg/ml of the anti-CD105 antibody or, antigen-binding fragment thereof.

13. The formulation of claim 1, comprising about 50 mg/ml of the anti-CD105 antibody or, antigen-binding fragment thereof.

14. The formulation of claim 1, comprising about 100 mg/ml of the anti-CD105 antibody or, antigen-binding fragment thereof.

15. The formulation of claim 1, wherein said buffering agent is histidine or acetate.

16. The formulation of claim 15, comprising about 20 mM histidine or acetate.

17. The formulation of claim 1, wherein said formulation is formulated for intravitreal or intravenous administration.

18. The formulation of claim 1, further comprising an acceptable carrier or excipient.

19. The formulation of claim 18, wherein said carrier or excipient is a pharmaceutically acceptable carrier or excipient.

20. The formulation of claim 1, which is isotonic or hypertonic.

21. The formulation of claim 1, wherein the polyol is less than 300 mM and the formulation is made isotonic with a salt.

22. The formulation of claim 1, wherein at least 95% of the anti-CD105 antibody is present as monomer as measured by SEC following freezing and thawing cycles of the formulation.

23. The formulation of claim 1, wherein at least 95% of the anti-CD105 antibody is present as monomer as measured by SEC when subjected to agitation stress.

24. The formulation of claim 1, wherein the polyol is a sugar.

25. The formulation of claim 24, wherein said sugar is a non-reducing sugar.

26. The formulation of claim 25, wherein the non-reducing sugar is trehalose or sucrose.

27. The formulation of claim 26, comprising about 240 mM trehalose or sucrose.

28. The formulation of claim 24, wherein the sugar is sorbitol.

29. The formulation of claim 28, comprising about 240 mM sorbitol.

30. The formulation of claim 1, further comprising a surfactant.

31. The formulation of claim 30, wherein the surfactant is polysorbate 20, polysorbate 80 or Pluronic® F68.

32. A pre-filled syringe suitable for intravenous or intravitreal administration comprising the formulation of any of the preceding claims.

33. Use of a formulation comprising from about 1 mg/ml to about 150 mg/ml of an anti-CD105 antibody, or antigen-binding fragment thereof, from about 5mM to about 100 mM of a buffering agent, from about 50mM to about 1 M of a polyol, and a pH of about 4.0 to about 7.5, in the manufacture of a medicament for treating an angiogenesis-related disease in a subject in need thereof.

34. The use of claim 33, wherein said anti-CD105 antibody comprises a light chain variable region (V_L) having an amino acid sequence set forth as SEQ ID NO: 1; a light chain constant region (C_L) having an amino acid sequence set forth as SEQ ID NO: 2; a heavy chain variable region (V_H) having an amino acid sequence set forth as SEQ ID NO: 3; and a constant region (Fc) having an amino acid sequence set forth as SEQ ID NO: 4.

35. The use of claim 33, wherein said anti-CD105 antibody comprises a V_L CDR1 having an amino acid sequence set forth as SEQ ID NO: 5; a V_L CDR2 having an amino acid sequence set forth as SEQ ID NO: 6; a V_L CDR3 having an amino acid sequence set forth as SEQ ID NO: 7; a V_H CDR1 having an amino acid sequence set forth as SEQ ID NO: 8; a V_H CDR2 having an amino acid sequence set forth as SEQ ID NO: 9; and a V_H CDR3 having an amino acid sequence set forth as SEQ ID NO: 10.

36. The use of claim 33, comprising about 25 mg/ml anti-CD105 antibody or, antigen-binding fragment thereof.

37. The use of claim 33, comprising about 50 mg/ml anti-CD105 antibody or, antigen-binding fragment thereof.

38. The use of claim 33, comprising about 100 mg/ml anti-CD105 antibody or, antigen-binding fragment thereof.

39. The use of claim 33, wherein said formulation comprises less than 300 mM polyol and the formulation is made isotonic with a salt.

40. The use of claim 33, wherein said buffering agent is histidine or acetate.

41. The use of claim 40, comprising about 20 mM histidine or acetate.

42. The use of claim 33, wherein the polyol is a sugar.

43. The use of claim 42, wherein the sugar is a non-reducing sugar.

44. The use of claim 43, wherein the non-reducing sugar is trehalose or sucrose.

45. The use of claim 44, comprising about 240 mM trehalose or sucrose.

46. The use of claim 42, wherein the sugar is sorbitol.

47. The use of claim 46, comprising about 240 mM sorbitol.

48. The use of claim 33, wherein said formulation is administered intravitreally or intravenously.

49. The use of claim 33, further comprising a surfactant.

50. The use of claim 49, wherein the surfactant is polysorbate 20, polysorbate 80 or Pluronic® F68.

51. The use of claim 33, wherein the angiogenesis-related disease is a cancer, or a metastasis.

52. The use of claim 51, wherein the cancer is a solid tumor.

53. The use of claim 51, wherein the cancer is an epithelial based tumor.

54. The use of claim 51, wherein the cancer is a lung cancer, a melanoma, a breast cancer, a pancreatic cancer, an ovarian cancer, a colorectal cancer, a prostate cancer, a kidney cancer, a liver cancer (hepatocellular cancer), a uterine cancer, a neck cancer, a sarcoma, a myeloma, a brain cancer, or a lymphoma.

55. The use of claim 33, wherein said angiogenesis-related disease is an ophthalmologic condition.

56. The use of claim 55, wherein the ophthalmologic condition is age-related macular degeneration, diabetic retinopathy, or choroidal neovascularization.

57. The use of claim 56, wherein said age related macular degeneration (AMD) is wet AMD or dry AMD.

58. The use of claim 33, wherein said formulation is administered to said patient one or more times.

59. The use of claim 33, wherein said formulation is administered once per day, once per week, once per month, once bi-monthly, once every two months, once every three months, once every four months, once every 5 months, or once every 6 months.

60. The use of claim 33, wherein said formulation is administered until one or more signs or symptoms of said angiogenesis-related disease are reduced, wherein said one or more signs or symptoms are shrinking blood vessels, inhibiting endothelial cell proliferation associated with ocular disease, clearing signs or symptoms of bleeding, treating cloudy vision, providing stasis of vision loss, improving vision, and/or preventing leakage of blood vessels.

61. The use of claim 60, wherein said one or more signs or symptoms are reduced in severity or duration by about 2%, about 5%, about 10%, about 15%, about 20%, about 25%, about 30%, about 35%, about 40%, about 45%, about 50%, about 55%, about 60%, about 65%, about 70%, about 75%, about 80%, about 90%, about 95%, or about 100%.

62. The use of claim 60, wherein said one or more signs or symptoms are reduced in severity or duration by about 2-fold, about 5-fold, about 10-fold, about 15-fold, about 20-fold, about 25-fold, about 30-fold, about 35-fold, about 40-fold, about 45-fold, about 50-fold, about 55-fold, about 60-fold, about 65-fold, about 70-fold, about 75-fold, about 80-fold, about 90-fold, about 95-fold, about 100-fold or more.

63. The use of claim 33, wherein treatment results in improving the patient's condition and can be assessed by determining if one or more of the following factors has occurred: decreased cell proliferation, decreased numbers of cells, increased apoptosis, or decreased survival of at least a portion of the cells comprising the cell proliferative disorder.

64. The use of claim 33, wherein treatment results in partial or total elimination of a tumor or metastases and/or prolongation of survival of the patient.

65. Use of a formulation comprising from about 1 mg/ml to about 150 mg/ml of an anti-CD105 antibody, or antigen-binding fragment thereof, from about 5mM to about 100 mM of a buffering agent, from about 50mM to about 1 M of a polyol, a pH of about 4.0 to about 7.5, and optionally a surfactant, in the manufacture of a medicament for treating an ophthalmologic condition in a patient in need thereof.

66. The use of claim 65, wherein the ophthalmologic condition is age-related macular degeneration, diabetic retinopathy, or choroidal neovascularization.

67. The use of claim 66, wherein said age-related macular degeneration (AMD) is wet AMD or dry AMD.

68. The use of claim 65, wherein said anti-CD105 antibody comprises a light chain variable region (V_L) having an amino acid sequence set forth as SEQ ID NO: 1; a light chain constant region (C_L) having an amino acid sequence set forth as SEQ ID NO: 2; a heavy chain variable region (V_H) having an amino acid sequence set forth as SEQ ID NO: 3; and a constant region (Fc) having an amino acid sequence set forth as SEQ ID NO: 4.

69. The use of claim 65, wherein said anti-CD105 antibody comprises a V_L CDR1 having an amino acid sequence set forth as SEQ ID NO: 5; a V_L CDR2 having an amino acid sequence set forth as SEQ ID NO: 6; a V_L CDR3 having an amino acid sequence set forth as SEQ ID NO: 7; a V_H CDR1 having an amino acid sequence set forth as SEQ ID NO: 8; a V_H CDR2 having an amino acid sequence set forth as SEQ ID NO: 9; and a V_H CDR3 having an amino acid sequence set forth as SEQ ID NO: 10.

70. The use of claim 65, wherein said one or more signs or symptoms are shrinking blood vessels, inhibiting endothelial cell proliferation associated with ocular disease, clearing

signs or symptoms of bleeding, treating cloudy vision, providing stasis of vision loss, improving vision, and/or preventing leakage of blood vessels.

71. The use of claim 65, wherein said one or more signs or symptoms are reduced in severity or duration by about 2%, about 5%, about 10%, about 15%, about 20%, about 25%, about 30%, about 35%, about 40%, about 45%, about 50%, about 55%, about 60%, about 65%, about 70%, about 75%, about 80%, about 90%, about 95%, or about 100%.

72. The use of claim 65, wherein said one or more signs or symptoms are reduced in severity or duration by about 2-fold, about 5-fold, about 10-fold, about 15-fold, about 20-fold, about 25-fold, about 30-fold, about 35-fold, about 40-fold, about 45-fold, about 50-fold, about 55-fold, about 60-fold, about 65-fold, about 70-fold, about 75-fold, about 80-fold, about 90-fold, about 95-fold, about 100-fold or more.

73. The use of claim 65, wherein said formulation comprises less than 300 mM polyol and the formulation is made isotonic with a salt.

74. Use of a formulation comprising from about 1 mg/ml to about 150 mg/ml of an anti-CD105 antibody, or antigen-binding fragment thereof, from about 50mM to about 100 mM of a buffering agent, from about 50mM to about 1 M of a polyol, and a pH of about 4.0 to about 7.5, in the manufacture of a medicament for preventing or treating a cancer or metastasis in a subject in need thereof.

75. The use of claim 74, wherein said anti-CD105 antibody comprises a light chain variable region (V_L) having an amino acid sequence set forth as SEQ ID NO: 1; a light chain constant region (C_L) having an amino acid sequence set forth as SEQ ID NO: 2; a heavy chain variable region (V_H) having an amino acid sequence set forth as SEQ ID NO: 3; and a constant region (Fc) having an amino acid sequence set forth as SEQ ID NO: 4.

76. The use of claim 74, wherein said anti-CD105 antibody comprises a VL CDR1 having an amino acid sequence set forth as SEQ ID NO: 5; a VL CDR2 having an amino acid sequence set forth as SEQ ID NO: 6; a VL CDR3 having an amino acid sequence set forth as SEQ ID NO: 7; a VH CDR1 having an amino acid sequence set forth as SEQ ID NO: 8; a VH CDR2 having an amino acid sequence set forth as SEQ ID NO: 9; and a VH CDR3 having an amino acid sequence set forth as SEQ ID NO: 10.

77. The use of claim 74, wherein administration of the formulation prolongs the life of the subject.

78. The use of claim 74, wherein said cancer is a primary tumor or a metastatic tumor.

79. The use of claim 74, wherein said cancer is a solid tumor.

80. The use of claim 79, wherein said solid tumor is of a tissue or organ selected from among skin, melanoma, lung, pancreas, breast, ovary, colon, rectum, stomach, thyroid, larynx, prostate, neck, eye, mouth, throat, esophagus, chest, bone, testis, lymphoid, marrow, bone, sarcoma, sweat gland, liver, kidney and brain.

81. The use of claim 80, wherein said solid tumor is a colon tumor, a breast tumor, a kidney tumor, a lung tumor, a prostate tumor, an ovarian tumor, or a metastasis of any of such tumors.

82. The use of claim 74, wherein treatment results in improving the subject's condition and can be assessed by determining if one or more of the following factors has occurred: decreased cell proliferation, decreased numbers of cells, increased apoptosis, or decreased survival of at least a portion of the cells comprising the cell proliferative disorder.

83. The use of claim 74, wherein treatment results in partial or total elimination of a tumor or metastases and/or prolongation of survival of the patient.

84. The use of claim 74, wherein said one or more signs or symptoms are reduced in severity or duration by about 2%, about 5%, about 10%, about 15%, about 20%, about 25%, about 30%, about 35%, about 40%, about 45%, about 50%, about 55%, about 60%, about 65%, about 70%, about 75%, about 80%, about 90%, about 95%, or about 100%.

85. The use of claim 74, wherein said one or more signs or symptoms are reduced in severity or duration by about 2-fold, about 5-fold, about 10-fold, about 15-fold, about 20-fold, about 25-fold, about 30-fold, about 35-fold, about 40-fold, about 45-fold, about 50-fold, about 55-fold, about 60-fold, about 65-fold, about 70-fold, about 75-fold, about 80-fold, about 90-fold, about 95-fold, about 100-fold or more.

86. The use of claim 74, comprising about 25 mg/ml anti-CD105 antibody or, antigen-binding fragment thereof.

87. The use of claim 74, comprising about 50 mg/ml anti-CD105 antibody or, antigen-binding fragment thereof.

88. The use of claim 74, comprising about 100 mg/ml anti-CD105 antibody or, antigen-binding fragment thereof.

89. The use of claim 74, wherein said buffering agent is histidine or acetate.

90. The use of claim 89, comprising about 20 mM histidine or acetate.

91. The use of claim 74, wherein the polyol is a sugar.

92. The use of claim 91, wherein said sugar is a non-reducing sugar.

93. The use of claim 92, wherein the non-reducing sugar is trehalose or sucrose.

94. The use of claim 93, comprising about 240 mM trehalose or sucrose.

95. The use of claim 91, wherein said sugar is sorbitol.

96. The use of claim 95, comprising about 240 mM sorbitol.

97. The use of claim 74, wherein said formulation comprises less than 300 mM polyol and the formulation is made isotonic with a salt.

98. The use of claim 74, further comprising a surfactant.

99. The use of claim 98, wherein the surfactant is polysorbate 20, polysorbate 80 or Pluronic® F68.

100. The use of claim 74, wherein said formulation is administered intravenously.

101. The formulation of claim 1, wherein said formulation comprises any one of the formulations 1-39 of Table 1.

102. A pre-filled syringe comprising a formulation of claim 101.

103. Use of a formulation of claim 101 for the treatment of an angiogenesis-related disease.

104. Use of a formulation of claim 101 in the manufacture of a medicament for the treatment of an angiogenesis-related disease.

105. The use of claim 54, wherein the brain cancer is a glioblastoma multiforme or glioma.

106. The use of claim 80, wherein the solid tumor is a brain cancer that is a glioblastoma multiforme or glioma.

CLAIMS

WHAT IS CLAIMED IS:

1. A formulation comprising from 1 mg/ml to 150 mg/ml of an anti-CD105 antibody, or antigen-binding fragment thereof, from 5mM to 100 mM of a buffering agent, from 50mM to 1 M of a polyol, and a pH of from 4.0 to 5.5.

2. The formulation of claim 1, wherein at least 95% of the anti-CD105 antibody is present as a monomer following storage at 2 to 8° C for at least 12 months as measured by size exclusion chromatography (SEC).

3. The formulation of claim 1, wherein at least 95% of the anti-CD105 antibody is present as a monomer following storage at 25° C for at least 6 months as measured by size exclusion chromatography (SEC).

4. The formulation of claim 1, wherein at least 90% of the anti-CD105 antibody is present as a monomer following storage at 25° C for at least 6 months as measured by size exclusion chromatography (SEC).

5. The formulation of claim 1, wherein said buffering agent is histidine or phosphate buffered saline.

6. The formulation of claim 1, wherein the buffering agent is acetate and the pH is 4.

7. The formulation of claim 1 wherein the buffering agent is histidine and the pH is 5.5.

8. The formulation of claim 1, wherein the anti-CD105 antibody, or antigen-binding fragment thereof, displays 50 to 150% binding by a CD105 ELISA binding assay after storage at 2 to 8 °C for at least 12 months.

9. The formulation of claim 1, wherein the average isoelectric point (pI) of the anti-CD105 antibody is from 8.7 to 9.2 after storage at 2 to 8° C for at least 12 months, as measured by capillary electrophoresis-isoelectric focusing.

10. The formulation of claim 1, wherein said anti-CD105 antibody comprises a light chain variable region (V_L) having an amino acid sequence set forth as SEQ ID NO: 1; a light chain constant region (C_L) having an amino acid sequence set forth as SEQ ID NO: 2; a heavy chain variable region (V_H) having an amino acid sequence set forth as SEQ ID NO: 3; and a constant region (Fc) having an amino acid sequence set forth as SEQ ID NO: 4.

11. The formulation of claim 1, wherein said anti-CD105 antibody comprises a V_L CDR1 having an amino acid sequence set forth as SEQ ID NO: 5; a V_L CDR2 having an amino acid sequence set forth as SEQ ID NO: 6; a V_L CDR3 having an amino acid sequence

set forth as SEQ ID NO: 7; a V_H CDR1 having an amino acid sequence set forth as SEQ ID NO: 8; a V_H CDR2 having an amino acid sequence set forth as SEQ ID NO: 9; and a V_H CDR3 having an amino acid sequence set forth as SEQ ID NO: 10.

12. The formulation of claim 1, comprising 25 mg/ml of the anti-CD105 antibody or, antigen-binding fragment thereof.

13. The formulation of claim 1, comprising 50 mg/ml of the anti-CD105 antibody or, antigen-binding fragment thereof.

14. The formulation of claim 1, comprising 100 mg/ml of the anti-CD105 antibody or, antigen-binding fragment thereof.

15. The formulation of claim 1, wherein said buffering agent is histidine or acetate.

16. The formulation of claim 15, comprising 20 mM histidine or acetate.

17. The formulation of claim 1, wherein said formulation is formulated for intravitreal or intravenous administration.

18. The formulation of claim 1, further comprising an acceptable carrier or excipient.

19. The formulation of claim 18, wherein said carrier or excipient is a pharmaceutically acceptable carrier or excipient.

20. The formulation of claim 1, which is isotonic or hypertonic.

21. The formulation of claim 1, wherein the polyol is less than 300 mM and the formulation is made isotonic with a salt.

22. The formulation of claim 1, wherein at least 95% of the anti-CD105 antibody is present as monomer as measured by SEC following freezing and thawing cycles of the formulation.

23. The formulation of claim 1, wherein at least 95% of the anti-CD105 antibody is present as monomer as measured by SEC when subjected to agitation stress.

24. The formulation of claim 1, wherein the polyol is a sugar.

25. The formulation of claim 24, wherein said sugar is a non-reducing sugar.

26. The formulation of claim 25, wherein the non-reducing sugar is trehalose or sucrose.

27. The formulation of claim 26, comprising 240 mM trehalose or sucrose.

28. The formulation of claim 24, wherein the sugar is sorbitol.

29. The formulation of claim 28, comprising 240 mM sorbitol.

30. The formulation of claim 1, further comprising a surfactant.

31. The formulation of claim 30, wherein the surfactant is polysorbate 20, polysorbate 80 or Pluronic® F68.

32. A pre-filled syringe suitable for intravenous administration comprising the formulation of any of the preceding claims.

33. A pre-filled syringe suitable for intravitreal administration comprising a formulation of claim 12.

34. Use of a formulation comprising from about 1 mg/ml to about 150 mg/ml of an anti-CD105 antibody, or antigen-binding fragment thereof, from 5mM to 100 mM of a buffering agent, from 50mM to 1 M of a polyol, and a pH of from 4.0 to 5.5, in the manufacture of a medicament for treating an angiogenesis-related disease in a subject in need thereof.

35. The use of claim 34, wherein said anti-CD105 antibody comprises a light chain variable region (V_L) having an amino acid sequence set forth as SEQ ID NO: 1; a light chain constant region (C_L) having an amino acid sequence set forth as SEQ ID NO: 2; a heavy chain variable region (V_H) having an amino acid sequence set forth as SEQ ID NO: 3; and a constant region (Fc) having an amino acid sequence set forth as SEQ ID NO: 4.

36. The use of claim 34, wherein said anti-CD105 antibody comprises a V_L CDR1 having an amino acid sequence set forth as SEQ ID NO: 5; a V_L CDR2 having an amino acid sequence set forth as SEQ ID NO: 6; a V_L CDR3 having an amino acid sequence set forth as SEQ ID NO: 7; a V_H CDR1 having an amino acid sequence set forth as SEQ ID NO: 8; a V_H CDR2 having an amino acid sequence set forth as SEQ ID NO: 9; and a V_H CDR3 having an amino acid sequence set forth as SEQ ID NO: 10.

37. The use of claim 34, comprising 25 mg/ml anti-CD105 antibody or, antigen-binding fragment thereof.

38. The use of claim 34, comprising 50 mg/ml anti-CD105 antibody or, antigen-binding fragment thereof.

39. The use of claim 34, comprising 100 mg/ml anti-CD105 antibody or, antigen-binding fragment thereof.

40. The use of claim 34, wherein said formulation comprises less than 300 mM polyol and the formulation is made isotonic with a salt.

41. The use of claim 34, wherein said buffering agent is histidine or acetate.

42. The use of claim 41, comprising 20 mM histidine or acetate.

43. The use of claim 34, wherein the polyol is a sugar.

44. The use of claim 43, wherein the sugar is a non-reducing sugar.

45. The use of claim 44, wherein the non-reducing sugar is trehalose or sucrose.

46. The use of claim 45, comprising ~~about~~ 240 mM trehalose or sucrose.

47. The use of claim 43, wherein the sugar is sorbitol.

48. The use of claim 47, comprising ~~about~~ 240 mM sorbitol.

49. The use of claim 34, wherein said formulation is administered intravitreally or intravenously.

50. The use of claim 34, further comprising a surfactant.

51. The use of claim 50, wherein the surfactant is polysorbate 20, polysorbate 80 or Pluronic® F68.

52. The use of claim 34, wherein the angiogenesis-related disease is a cancer, or a metastasis.

53. The use of claim 52, wherein the cancer is a solid tumor.

54. The use of claim 52, wherein the cancer is an epithelial based tumor.

55. The use of claim 52, wherein the cancer is a lung cancer, a melanoma, a breast cancer, a pancreatic cancer, an ovarian cancer, a colorectal cancer, a prostate cancer, a kidney cancer, a liver cancer (hepatocellular cancer), a uterine cancer, a neck cancer, a sarcoma, a myeloma, a brain cancer, or a lymphoma.

56. The use of claim 34, wherein said angiogenesis-related disease is an ophthalmologic condition.

57. The use of claim 56, wherein the ophthalmologic condition is age-related macular degeneration, diabetic retinopathy, or choroidal neovascularization.

58. The use of claim 57, wherein said age related macular degeneration (AMD) is wet AMD or dry AMD.

59. The use of claim 34, wherein said formulation is administered to said patient one or more times.

60. The use of claim 34, wherein said formulation is administered once per day, once per week, once per month, once bi-monthly, once every two months, once every three months, once every four months, once every 5 months, or once every 6 months.

61. The use of claim 34, wherein said formulation is administered until one or more signs or symptoms of said angiogenesis-related disease are reduced, wherein said one or more signs or symptoms are shrinking blood vessels, inhibiting endothelial cell proliferation associated with ocular disease, clearing signs or symptoms of bleeding, treating cloudy

vision, providing stasis of vision loss, improving vision, and/or preventing leakage of blood vessels.

62. The use of claim 34, wherein treatment results in improving the patient's condition and can be assessed by determining if one or more of the following factors has occurred: decreased cell proliferation, decreased numbers of cells, increased apoptosis, or decreased survival of at least a portion of the cells comprising the cell proliferative disorder.

63. The use of claim 34, wherein treatment results in partial or total elimination of a tumor or metastases and/or prolongation of survival of the patient.

64. Use of a formulation comprising from 1 mg/ml to 150 mg/ml of an anti-CD105 antibody, or antigen-binding fragment thereof, from 5mM to 100 mM of a buffering agent, from 50mM to 1 M of a polyol, a pH of from 4.0 to 7.5, and optionally a surfactant, in the manufacture of a medicament for treating an ophthalmologic condition in a patient in need thereof, wherein the ophthalmologic condition is age-related macular degeneration, diabetic retinopathy, or choroidal neovascularization.

65. The use of claim 64, wherein said age-related macular degeneration (AMD) is wet AMD or dry AMD.

66. The use of claim 64, wherein said anti-CD105 antibody comprises a light chain variable region (V_L) having an amino acid sequence set forth as SEQ ID NO: 1; a light chain constant region (C_L) having an amino acid sequence set forth as SEQ ID NO: 2; a heavy chain variable region (V_H) having an amino acid sequence set forth as SEQ ID NO: 3; and a constant region (Fc) having an amino acid sequence set forth as SEQ ID NO: 4.

67. The use of claim 64, wherein said anti-CD105 antibody comprises a V_L CDR1 having an amino acid sequence set forth as SEQ ID NO: 5; a V_L CDR2 having an amino acid sequence set forth as SEQ ID NO: 6; a V_L CDR3 having an amino acid sequence set forth as SEQ ID NO: 7; a V_H CDR1 having an amino acid sequence set forth as SEQ ID NO: 8; a V_H CDR2 having an amino acid sequence set forth as SEQ ID NO: 9; and a V_H CDR3 having an amino acid sequence set forth as SEQ ID NO: 10.

68. The use of claim 64, wherein said one or more signs or symptoms are shrinking blood vessels, inhibiting endothelial cell proliferation associated with ocular disease, clearing signs or symptoms of bleeding, treating cloudy vision, providing stasis of vision loss, improving vision, and/or preventing leakage of blood vessels.

69. The use of claim 64, wherein said formulation comprises less than 300 mM polyol and the formulation is made isotonic with a salt.

70. Use of a formulation comprising from about 1 mg/ml to about 150 mg/ml of an anti-CD105 antibody, or antigen-binding fragment thereof, from 50mM to 100 mM of a buffering agent, from 50mM to 1 M of a polyol, and a pH of from_4.0 to 7.5, in the manufacture of a medicament for preventing or treating a cancer or metastasis in a subject in need thereof.

71. The use of claim 70, wherein said anti-CD105 antibody comprises a light chain variable region (V_L) having an amino acid sequence set forth as SEQ ID NO: 1; a light chain constant region (C_L) having an amino acid sequence set forth as SEQ ID NO: 2; a heavy chain variable region (V_H) having an amino acid sequence set forth as SEQ ID NO: 3; and a constant region (Fc) having an amino acid sequence set forth as SEQ ID NO: 4.

72. The use of claim 70, wherein said anti-CD105 antibody comprises a VL CDR1 having an amino acid sequence set forth as SEQ ID NO: 5; a VL CDR2 having an amino acid sequence set forth as SEQ ID NO: 6; a VL CDR3 having an amino acid sequence set forth as SEQ ID NO: 7; a VH CDR1 having an amino acid sequence set forth as SEQ ID NO: 8; a VH CDR2 having an amino acid sequence set forth as SEQ ID NO: 9; and a VH CDR3 having an amino acid sequence set forth as SEQ ID NO: 10.

73. The use of claim 70, wherein administration of the formulation prolongs the life of the subject.

74. The use of claim 70, wherein said cancer is a primary tumor or a metastatic tumor.

75. The use of claim 70, wherein said cancer is a solid tumor.

76. The use of claim 75, wherein said solid tumor is of a tissue or organ selected from among skin, melanoma, lung, pancreas, breast, ovary, colon, rectum, stomach, thyroid, larynx, prostate, neck, eye, mouth, throat, esophagus, chest, bone, testis, lymphoid, marrow, bone, sarcoma, sweat gland, liver, kidney and brain.

77. The use of claim 76, wherein said solid tumor is a colon tumor, a breast tumor, a kidney tumor, a lung tumor, a prostate tumor, an ovarian tumor, or a metastasis of any of such tumors.

78. The use of claim 70, wherein treatment results in improving the subject's condition and can be assessed by determining if one or more of the following factors has occurred: decreased cell proliferation, decreased numbers of cells, increased apoptosis, or decreased survival of at least a portion of the cells comprising the cell proliferative disorder.

79. The use of claim 70, wherein treatment results in partial or total elimination of a tumor or metastases and/or prolongation of survival of the patient.

80. The use of claim 70, comprising 25 mg/ml anti-CD105 antibody or, antigen-binding fragment thereof.

81. The use of claim 70, comprising 50 mg/ml anti-CD105 antibody or, antigen-binding fragment thereof.

82. The use of claim 70, comprising 100 mg/ml anti-CD105 antibody or, antigen-binding fragment thereof.

83. The use of claim 70, wherein said buffering agent is histidine or acetate.

84. The use of claim 83, comprising 20 mM histidine or acetate.

85. The use of claim 70, wherein the polyol is a sugar.

86. The use of claim 85, wherein said sugar is a non-reducing sugar.

87. The use of claim 86, wherein the non-reducing sugar is trehalose or sucrose.

88. The use of claim 87, comprising 240 mM trehalose or sucrose.

89. The use of claim 85, wherein said sugar is sorbitol.

90. The use of claim 89, comprising 240 mM sorbitol.

91. The use of claim 70, wherein said formulation comprises less than 300 mM polyol and the formulation is made isotonic with a salt.

92. The use of claim 70, further comprising a surfactant.

93. The use of claim 92, wherein the surfactant is polysorbate 20, polysorbate 80 or Pluronic® F68.

94. The use of claim 70, wherein said formulation is administered intravenously.

94. A formulation comprising any one of the formulations 1-39 of Table 1.

95. A pre-filled syringe comprising a formulation of claim 94.

96. Use of a formulation of claim 95, in the manufacture of a medicament for the treatment of an angiogenesis-related disease.

97. The use of claim 55, wherein the brain cancer is a glioblastoma multiforme or glioma.

98. The use of claim 76, wherein the solid tumor is a brain cancer that is a glioblastoma multiforme or glioma.